Trial reportDrug and alcohol dependence2013
Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Trial report in Drug and alcohol dependence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials.Systematic reviews · 2021Pooled it
- Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.Journal of substance abuse treatment · 2019Pooled it
- Retention in medication-assisted treatment for opiate dependence: A systematic review.Journal of addictive diseases · 2016Pooled it
- Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.Journal of substance abuse treatment · 2015Pooled it
- Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions.Substance abuse treatment, prevention, and policy · 2014Trial
- Correction: Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.AIDS and behavior · 2025Article
- Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.AIDS and behavior · 2025Article
- Considerations when prescribing opioid agonist therapies for people living with HIV.Expert review of clinical pharmacology · 2024Review
- Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis.Drug and alcohol dependence · 2024Article
- Observational
- Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder.Drug and alcohol dependence · 2023Article
- Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.Addiction science & clinical practice · 2022Article
- Effect of police action on low-barrier substance use disorder service utilization.Harm reduction journal · 2022Article
- Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.Journal of substance abuse treatment · 2022Review
- The "black box" of treatment: Patients' perspective on what works in opioid maintenance treatment for opioid dependence.Substance abuse treatment, prevention, and policy · 2021Article
- Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies.The International journal on drug policy · 2021Article
- Correlates of death during outpatient treatment for opioid use disorder: A national study.Journal of substance abuse treatment · 2020Article
- Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.British journal of clinical pharmacology · 2019Article
- Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.Contemporary clinical trials · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsDetermine the extent to which buprenorphine injectors continue treatment with buprenorphine-naloxone or methadone, and the impact of these treatments on substance use and HIV risk in the Republic of Georgia.
methodsRandomized controlled 12-week trial of daily-observed methadone or buprenorphine-naloxone followed by a dose taper, referral to ongoing treatment, and follow-up at week 20 at the Uranti Clinic in Tbilisi, Republic of Georgia. Eighty consenting treatment-seeking individuals (40/group) aged 25 and above who met ICD-10 criteria for opioid dependence with physiologic features and reported injecting buprenorphine 10 or more times in the past 30 days. Opioid use according to urine tests and self-reports, treatment retention, and HIV risk behavior as determined by the Risk Assessment Battery.
resultsMean age of participants was 33.7 (SD5.7), 4 were female, mean history of opioid injection use was 5.8 years (SD4.6), none were HIV+ at intake or at the 12-week assessment and 73.4% were HCV+. Sixty-eight participants (85%) completed the 12-week medication phase (33 from methadone and 35 from buprenorphine/naloxone group); 37 (46%) were in treatment at the 20-week follow-up (21 from methadone and 16 from the buprenorphine/naloxone group). In both study arms, treatment resulted in a marked reduction in unprescribed buprenorphine, other opioid use, and HIV injecting risk behavior with no clinically significant differences between the two treatment arms.
conclusionsDaily observed methadone or buprenorphine-naloxone are effective treatments for non-medical buprenorphine and other opioid use in the Republic of Georgia and likely to be useful for preventing HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.